Index removal puts Intuitive Surgical stock back under the microscope

Intuitive Surgical (ISRG) was recently dropped from the Russell Top 50 Index, a move that can reshape institutional ownership patterns, trading flows, and short term volatility around the stock.

For you as an investor, this index change sits alongside an active debate about Intuitive Surgical's valuation, long term business outlook, and recent adjustments to its surgical tool offerings. All of these factors are influencing sentiment and trading interest.

Against this backdrop, Intuitive Surgical's share price has fallen 28% year to date to around $404.70, and the 1 year total shareholder return of a 24.17% decline contrasts with a 3 year total shareholder return of 18.35% and a 5 year total shareholder return of 29.41%. This points to fading recent momentum despite longer term gains.

If you are weighing how this mix of index changes, sentiment shifts, and valuation debate might compare with other opportunities in medical technology, it could be worth scanning 39 healthcare AI stocks

So with Intuitive Surgical down sharply this year, solid revenue and net income figures, and a market value still above $140b, is the stock quietly offering value, or is the market already pricing in the company’s future growth?

Most Popular Narrative: 24% Undervalued

On the most followed narrative, Intuitive Surgical's fair value is set at $532.46, which stands above the recent $404.70 close and frames the current pullback in a very different light.

Over the next 5 years I calculate with (actual values from 18.01.26, price/shr at 533 USD): Revenue growth per year: 12% (currently at 14.7%). We saw the peak of revenue growth with nearly 15%. Now even 12% is ambitious, but with the subscription-like revenues from spare parts and software licenses, based on a still growing base of installed systems, it seems realistic. Profit margin: 30% (currently at 28.6%), because spare parts in general have higher margins than system sales, and the sales from spare parts are still growing. Future P/E: 50 (currently at 69). The high P/Es are typical for fast growers, but over time the P/E may go down. I see for the next 5 years 50, and in 10 years it could come down to 40. Interest rate: 6.77% (same as current). This leads to a fair value of 533 USD, which means ISRG trades with 0.5% at fair value.

Want to see what sits underneath that $532.46 figure? The narrative leans on steady revenue expansion, firm margins, and a rich future earnings multiple. Curious how those pieces combine into one valuation story?

Result: Fair Value of $532.46 (UNDERVALUED)

However, this depends on Intuitive Surgical sustaining its current revenue and net income profile, as well as on market appetite for a high P/E multiple not cooling sharply.

Another View: Intuitive Surgical Looks Expensive On Earnings

The user narrative argues Intuitive Surgical is 24% undervalued at around $404.70, but the earnings based view points the other way. The stock trades on a P/E of 48.1x versus 26.2x for the US Medical Equipment industry, 26.1x for peers, and a fair ratio of 31.3x. This implies meaningful valuation risk if sentiment cools.

If you want to see how those earnings based signals stack up in detail, including how they compare with the fair ratio over time, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The tug of war between valuation concerns and long term optimism around Intuitive Surgical is clear. Move quickly and test the data against your own expectations by reviewing the 4 key rewards.

Looking for more investment ideas beyond Intuitive Surgical?

Before you move on, turn this research momentum into action by lining up fresh ideas that match your style instead of waiting for the next headline to appear.

• Target potential mispricing by scanning companies that screen as 44 high quality undervalued stocks and see which ones deserve a closer look alongside Intuitive Surgical.
• Prioritise staying power by reviewing stocks in the solid balance sheet and fundamentals stocks screener (48 results) so you can focus on businesses with financial strength at their core.
• Get ahead of the crowd by tracking opportunities in the screener containing 19 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.